The absence of an association between CYP11A1 (ttta)4 and prostate cancer development was confirmed in another study by Cicek et al. (2005); however, they were not able to corroborate Kumazama’s findings in which lack of CYP11A1 (tttta)4 was associated with increased stage and grade of prostate cancer. This evidence concerns the gene CYP11A1 and prostate cancer.